# Heartflow, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Heartflow, Inc.).

## Overview

Heartflow, Inc. develops software-based cardiovascular diagnostics that analyze coronary CT angiography (CCTA) images to help physicians assess coronary artery disease without invasive procedures. Its commercial platform is sold on a usage-driven basis, with core products including Heartflow FFRCT Analysis and Heartflow Plaque Analysis, and it is expanding into workflow tools such as Heartflow RoadMap and the planned PCI Planner.

## Products & services

• Heartflow FFRCT Analysis for non-invasive CAD assessment
• Heartflow Plaque Analysis for coronary plaque characterization
• Heartflow RoadMap Analysis as a workflow efficiency tool
• Heartflow PCI Planner, expected to launch in 2026
• Cloud-based image analysis and physician reporting platform

- **FFRCT Analysis** (98%) — AI-enabled coronary physiology analysis used to assess blood flow restriction from CCTA scans.
- **Plaque Analysis** (2%) — Coronary plaque assessment product used to support treatment decisions and risk stratification.
- **Workflow tools** (0%) — RoadMap and planned PCI Planner features that improve workflow efficiency and retention.

- Heartflow FFRCT Analysis for non-invasive CAD assessment
- Heartflow Plaque Analysis for coronary plaque characterization
- Heartflow RoadMap Analysis as a workflow efficiency tool
- Heartflow PCI Planner, expected to launch in 2026
- Cloud-based image analysis and physician reporting platform

## Customers

Heartflow sells primarily to hospitals, health systems, and imaging centers that order analyses for patients being evaluated for coronary artery disease. The company also depends on referring physicians and reading physicians within those accounts, because utilization rises when clinicians adopt the platform as part of routine CAD workups.

- **Large health systems** (primary) — Multi-facility systems that buy access across several accounts and drive meaningful case volume.
- **Individual hospital and imaging accounts** (primary) — Facilities that order FFRCT and plaque analyses for routine CAD evaluation.
- **Referring physicians** (secondary) — Cardiologists and other clinicians who choose Heartflow to avoid invasive testing and improve triage.
- **Payors and reimbursement decision-makers** (primary) — Government and third-party payors whose coverage and payment policies determine adoption economics.

- Hospitals and health systems that deploy the platform across multiple sites
- Individual imaging facilities that submit CCTA scans for analysis
- Referring cardiologists and physicians who drive test ordering
- Reading physicians and radiology/cardiology teams who use the results
- Government and commercial payors that influence adoption through coverage

## Geography

Heartflow’s commercial base is centered in the United States, where it had more than 1,100 accounts as of December 31, 2024. It also has regulatory approval and commercial presence in the United Kingdom, European Union, Australia, Canada, and Japan, supported by small direct commercial teams in those markets.

- United States is the core market and main source of installed-base growth
- International presence includes the UK, EU, Australia, Canada, and Japan
- Small direct commercial teams support non-U.S. markets
- No manufacturing footprint was disclosed; business is software and service based
- Coverage and reimbursement vary by country and affect adoption speed

## Strategy

Heartflow is focused on expanding utilization within its installed base while adding new accounts through a scalable, low-capex commercial model. It is also broadening the platform beyond FFRCT into plaque assessment and future PCI planning, aiming to deepen clinical relevance and improve customer retention.

- **Grow utilization at existing accounts** (short-term) — Revenue is usage-driven, so more cases per account directly increase sales.
- **Expand Plaque Analysis adoption** (medium-term) — The product is a long-term growth driver but still early in commercialization.
- **Build a broader platform around workflow and PCI planning** (medium-term) — Adjacent tools can improve retention and make the platform more embedded in care pathways.
- **Scale international commercialization** (long-term) — Approved markets outside the U.S. provide additional growth without changing the core product.

- Increase account adoption and utilization within the installed base
- Expand reimbursement and market education for Plaque Analysis
- Use workflow tools to improve retention and physician loyalty
- Scale internationally in approved markets with small direct teams
- Leverage AI and automation to improve product performance

## Risks

Heartflow is highly exposed to reimbursement policy, physician adoption, and customer concentration because most revenue comes from one usage-based product. It also faces technology, regulatory, and competitive risks tied to AI-driven diagnostics, while Plaque Analysis remains early and may not reach expected utilization.

- **Dependence on a single core product** [high] — Substantially all revenue is generated by Heartflow FFRCT Analysis, making results sensitive to one offering.
- **Reimbursement and coverage risk** [high] — If payors do not cover the platform or reduce payment amounts, provider adoption can slow materially.
- **Customer concentration** [medium] — A small number of large health systems can represent a disproportionate share of revenue.
- **AI and model performance risk** [high] — Incorrect design, poor data, bugs, or cybersecurity issues could impair product performance and create liability.
- **Plaque Analysis commercialization risk** [medium] — The product is still nascent and may not achieve expected market acceptance or utilization.

- Revenue depends heavily on Heartflow FFRCT Analysis
- Coverage and reimbursement changes can quickly affect adoption
- Customer concentration can amplify the loss of a large health system
- AI model performance and regulatory compliance create product risk
- Competition and new technologies could reduce market share

## Accounting

Heartflow’s revenue is recognized when the requested analysis is delivered, so quarterly results can swing with case volume, customer mix, and utilization patterns. Investors should also watch estimates around stock-based compensation, capitalized software, contract fulfillment costs, royalties, and the treatment of debt conversion and repayment around the IPO.

- **Usage-based revenue recognition** — Can create volatility in reported revenue and margins
- **Seasonality and utilization variability** — Makes quarter-to-quarter comparisons less comparable
- **Capitalized software and contract fulfillment costs** — Affects gross margin and operating leverage
- **Stock-based compensation** — Impacts operating loss and non-cash expense profile
- **Debt conversion and repayment around IPO** — Affects interest expense, leverage, and cash flow presentation

- Usage-based revenue recognition depends on delivery timing of analyses
- Quarterly revenue is affected by seasonality and case volume fluctuations
- Cost of revenue includes production staff, hosting, software amortization, and royalties
- Capitalized internal-use software and fulfillment costs affect expense timing
- IPO-related debt conversion and repayment changed the capital structure

---

*Last updated: 2026-04-28T20:14:36.771520+00:00*